Discovery of Icenticaftor (QBW251), a Cystic Fibrosis Transmembrane Conductance Regulator Potentiator with Clinical Efficacy in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease
Darren Le Grand, Martin Gosling, Urs Baettig, Parmjit Bahra, Kamlesh Bala, Cara E. Brocklehurst, Emma Budd, Rebecca Butler, Atwood K. Cheung, Hedaythul Choudhury, Stephen P. Collingwood, Brian J. Cox, Henry Danahay, Lee J. Edwards, Brian Everatt, Ulrike Glaenzel, Anne‐Lise Glotin, Paul J. Groot‐Kormelink, Edward J. Hall, Julia Hatto, Catherine Howsham, Glyn A. Hughes, Anna King, Julia Koehler, Swarupa G. Kulkarni, Megan Lightfoot, Ian A. Nicholls, Christopher J. Page, Giles Pergl-Wilson, M. Oana Popa, Richard I. Robinson, David J. Rowlands, Tom Sharp, Matthew Spendiff, Emily Stanley, Oliver Steward, Roger Taylor, Pamela Tranter, Trixie Wagner, Hazel Watson, Gareth Williams, Penny Wright, Alice C. Young, David A. Sandham
Abstract
, which has subsequently progressed to deliver two positive clinical proofs of concept in patients with CF and COPD and is now being further developed as a novel therapeutic approach for COPD patients.